Danielle L. Aubele

Danielle L. Aubele has extensive work experience in the pharmaceutical industry. Danielle L. is currently working as the Senior Director of Medicinal Chemistry at Ambagon Therapeutics since August 2022. Prior to this, they worked at Bristol Myers Squibb as a Scientific Director from November 2020 to August 2022.

Before joining Bristol Myers Squibb, Danielle worked at MyoKardia for several roles. Danielle L. served as the Director of Chemistry from July 2020 to November 2020, Senior Scientist II from January 2016 to July 2020, and Sr. Scientist I from January 2013 to December 2016.

Danielle also has experience working at Elan Pharmaceuticals as a Staff Scientist from April 2010 to November 2012. Their responsibilities included driving the success of a Plk-2 kinase program chemistry effort and working closely with computational and structure-based design teams. Danielle L. also worked on a LRRK2 chemistry effort and delivered compounds for Alzheimer's disease. Additionally, they designed and synthesized novel chemical series for the Gamma Secretase inhibitor program.

Early in their career, Danielle gained experience as a Werkstudentin at Bayer AG, where they contributed to the development of protein immobilization techniques and researched polymerization methods for use on gold surfaces.

In summary, Danielle L. Aubele has a diverse background of roles and experiences in medicinal chemistry and pharmaceutical research and development, showcasing their expertise in various areas of drug discovery and development.

Danielle L. Aubele's education history begins with their earning a Bachelor of Science degree in Chemistry and German from Allegheny College, where they studied from 1995 to 1999. Danielle L. then pursued further education at the University of Pittsburgh, where they completed their Master of Science degree in Chemistry from 1999 to 2002. Finally, they obtained a Ph.D. in Chemistry from the University of Pittsburgh, completing their doctoral studies from 2002 to 2004.